Selected Publications

Collier C.N., Harper J.C., Cantrell W., Wang W., Foster K.W., and Elewski B.E. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 58: 56-9, 2008.

Elewski B.E., Abramovits W., Kempers S., Schlessinger J., Rosen T., Gupta A.K., Abraham S., and Rowell R. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 10: 1001-8, 2007.

Elewski B.E. Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model. Adv Ther. 24: 239-46, 2007.

Elewski B.E., Leonardi C., Gottlieb A.B., Strober B.E., Simiens, M.A., Dunn M., and Jahreis, A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Brit J Dermatol. 156: 138-142, 2007.

Draelos Z.D., Carter E., Maloney J.M., Elewski B.E., Poulin Y., Lynde C., and Garrett S. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. Journal of the Amer. Acad of Dermatol 56(3): 439-447, 2007.

Varma R., Cantrell W., Werlinger K., and Elewski B.E., . A new gel formulation of miconazole nitrate 2% for the treatment of chronic interigo. Cosmetic Dermatol. 20(1): 43.44, 2007.

Zhang A.Y., Elmets C.A., Camp W.L., and Elewski B.E.. New opportunities in preventive dermatology: How far should we go? Journal of the Amer Acad of Dermatology. 56(4): 675-676, 2007.

Elewski B.E. and Thiboutot D. A clinical overview of azelaic acid. Cutis (suppl 2)
Krueger G.G., Elewski B.E., Papp K., Wang A., and Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dematol; 54(3 Suppl 2) S112-9, 2006.

Elewski BE, Ling M.R., and Phillips T.J. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 7:646-50, 2006.

Elewski BE. Azelaic acid 15% gel for the treatment of Rosacea. Future Drugs. Expert Review of Dermatol. 1(4), 2006.

Parrish C.A., Sobera J.O., Robbins C.M., Cantrell W.C., Desmond R.A., and Elewski BE. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 5:339-340, 2006.

Draelos ZD, Carter E, Maloney JM, Elewski BE, Poulin Y, Lynde C, Garrett S.  Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.  J Amer Acad Dermatol.  56(3):  439-447, 2007.

Zhang AY, Elmets CA, Camp WL, Elewski BE.  New opportunities in preventive dermatology:  How far should we go?  J Amer Acad Dermatol.  56(4): 675-76m 2007.

Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE.  The prevalence of acne in adults ages twenty and older.  J Amer Acad Dermatol.  58(1): 56-59, 2007.

Elewski BE.  Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model.  Adv Ther. 24(2):  239-46, 2007.

Elewski BE, Abramovits W, Kempers S, Schlessinger J, Rosen T, Gupta AK, Abraham S, Rowell R.  A novel formulation of ketoconazole, 2% in the treatment of seborrheic dermatitis on multiple body regions.  J Drugs Dermatol. 6(10): 1001-1008m 2007.

Elewski BE, Wheeler CE.  An inspiring teacher.  Journal of Investigative Dermatology  127(8):  1850, 2007.

Elewski BE, Fleischer A, Pariser D.  In reference to the October 2004 comprehensive overview of rosacea therapy.  Letter/Reply.  J Am Acad Dermatol.  57(4): 728, 2007.

Elewski BE.  Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model.  Adv Ther.  24(2): 239-46, 2007.

Zhang AY, Camp WL, Elewski BE.  Advances in topical and systemic antifungals.  Dermatol Clin.  25(2):  165-83, 2007.

Elewski BE.  Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%.  Cutis.  79(1): 5708, 2007.

Cafardi J, Cantrell W, Wang W, Elmets CA, Elewski BE.  The safety and efficacy of high dose alefecept compared with a loading dose of alefecept in patients with chronic plaque psoriasis.  Skinmed.  7(2): 67-72, 2008.

Elewski BE, Caceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, Rachesky IJ, Sanchez-Bal V, Todd G, Wraith L, Cai B, Tavakkol A, Bakshi R, Nyirady J, Friedlander SF.  Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis:  Results of two randomized investigator-blinded, multicenter, international, controlled trials.  J Am Acad Dermatol.  59(1): 41-54, 2008.

Varma R, Cantrell W, Elmets C, Elewski BE.  Infliximab for the treatment of severe pustular psoriasis; 6 years later.  J Eur Acad Dermatol Venereol.  22(10): 1253-54, 2008.

Bentley D, Andea A, Holzer A, Elewski BE.  Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.  J Am Acad Dermatol.   60(3): 504-507, 2009.

Marks S, Varma R, Cantrell W, Chen S, Gold MH, Muellenhoff M, Elewski BE.  diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.  J Eur Acad Dermatol Venereol.  23(1): 42-5, 2009.

Elewski BE.  Results of a national rosacea patient survey:  common issues that concern rosacea sufferers.  J Drugs Dermatol.  8(2): 120-23, 2009.

Cathcart S, Cantrell W, Elewski BE.  Onychomycosis and diabetes.  J Eur Acad Dermatol Venereol.  23(10): 1119-22, 2009.

Elewski BE. Safe and effective treatment of seborrheic dermatitis.  Cutis. 83(6): 333-8, 2009.

Elewski BE.  Results of a national rosacea patient survey:  common issues that concern rosacea sufferers.  J Drugs Dermatol.  8(2): 120-3, 2009.

Click here to view further publications on pubmed.